S-ketamine concentrations are greatly increased by grapefruit juice
详细信息 查看全文
- 作者：Marko A. Peltoniemi (12)
Teijo I. Saari (3)
Nora M. Hagelberg (12)
Kari Laine (45)
Pertti J. Neuvonen (67)
Klaus T. Olkkola (12) klaus.olkkola@utu.fi - 关键词：Ketamine – ; Oral administration – ; Analgesics – ; Citrus paradisi (grapefruit juice) – ; Drug interaction – ; Cytochrome P450 CYP3A
- 刊名：European Journal of Clinical Pharmacology
- 出版年：2012
- 出版时间：June 2012
- 年：2012
- 卷：68
- 期：6
- 页码：979-986
- 全文大小：206.4 KB
- 参考文献：1. Petrenko AB, Yamakura T, Hiroshi B, Shimoji K (2003) The role of N-methyl-D-aspartate (NMDA) receptors in pain: a review. Anesth Analg 97:1108–1116
2. Bell RF, Eccleston C, Kalso E (2003) Ketamine as an adjuvant to opioids for cancer pain. A qualitative systematic review. J Pain Symptom Manag 26:867–875
3. Bell RF, Dahl JB, Moore RA, Kalso E (2005) Peri-operative ketamine for acute post-operative pain: a quantitative and qualitative systematic review. Acta Anesth Scand 49:1405–1428
4. Bell RF (2009) Ketamine for chronic non-cancer pain. Pain 141:210–214
5. Chong C, Schug SA, Page-Sharp M, Jenkins B, Ilett KF (2009) Development of a sublingual/oral formulation of ketamine for use in neuropathic pain: preliminary findings from a three-way randomized, crossover study. Clin Drug Investig 29:317–324
6. Huge V, Lauchart M, Magerl W, Schelling G, Beyer A, Thieme D, Azad SC (2010) Effects of low-dose intranasal (S)-ketamine in patients with neuropathic pain. Eur J Pain 14:387–394
7. Arendt-Nielsen L, Nielsen J, Petersen-Felix S, Schnider TW, Zbinden AM (1996) Effect of racemic micture and the S(+)-isomer of ketamine on temporal and spatial summation of pain. Br J Anaesth 77:625–631
8. Yanagihara Y, Kariya S, Ohtani M, Uchino K, Aoyama T, Yamamura Y, Iga T (2001) Involvement of CYP2B6 in n-demethylation of ketamine in human liver microsomes. Drug Metab Dispos 29:887–890
9. Hijazi Y, Boulieu R (2002) Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos 30:853–858
10. Grant IS, Nimmo WS, Clements JA (1981) Pharmacokinetics and analgesic effects of i.m. and oral ketamine. Br J Anaesth 53:805–810
11. Clements JA, Nimmo WS, Grant IS (1982) Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans. J Pharm Sci 71:539–542
12. Yanagihara Y, Ohtani M, Kariya S, Uchino K, Hiraishi T, Ashizawa N, Aoyama T, Yamamura Y, Yamada Y, Iga T (2003) Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers. Biopharm Drug Dispos 24:37–43
13. Ducharme MP, Warbasse LH, Edwards DJ (1995) Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther 57:485–491
14. Hanley MJ, Cancalon P, Widmer WW, Greenblatt DJ (2011) The effect of grapefruit juice on drug disposition. Expert Opin Drug Metab Toxicol 7:267–286
15. Dresser GK, Bailey DG, Leake BF, Schwarz UI, Dawson PA, Freeman DJ, Kim RB (2002) Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 71:11–20
16. Wang X, Wolkoff AW, Morris ME (2005) Flavonoids as a novel class of human organic anion-transporting polypeptide OATP1B1 (OAT-C) modulators. Drug Metab Dispos 33:1666–1672
17. Bailey DG (2010) Fruit juice inhibition of uptake transport: a new type of food-drug interaction. Br J Clin Pharmacol 70:645–655
18. Seden K, Dickinson L, Khoo S, Back D (2010) Grapefruit-drug interactions. Drugs 70:2373–2407
19. Eagling VA, Profit L, Back DJ (1999) Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br J Clin Pharmacol 48:543–552
20. Edwards DJ, Fitzsimmons ME, Schuetz EG, Yasuda K, Ducharme MP, Warbasse LH, Woster PM, Schuetz JD, Watkins P (1999) 6麓,7麓-Dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein. Clin Pharmacol Ther 65:237–244
21. Li P, Gallery PS, Gan LS, Balani SK (2007) Esterase inhibition by grapefruit juice flavonoids leading to a new drug interaction. Drug Metab Dispos 35:1203–1208
22. Li P, Callery PS, Gan LS, Balani SK (2007) Esterase inhibition attribute of grapefruit juice leading to a new drug interaction. Drug Metab Dispos 35:1023–1031
23. Nishimuta H, Tsujimoto M, Ogura K, Hiratsuka A, Ohtani H, Sawada Y (2005) Inhibitory effects of various beverages on ritodrine sulfation by recombinant human sulfotransferase isoforms SULT1A1 and SULT1A3. Pharm Res 22:1406–1410
24. Nishimuta H, Ohtani H, Tsujimoto M, Ogura K, Hiratsuka A, Sawada Y (2007) Inhibitory effects of various beverages on human recombinant sulfotransferase isoforms SULT1A1 and SULT1A3. Biopharm Drug Dispos 28:491–500
25. Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS (1997) The cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice. Eur J Clin Pharmacol 52:311–315
26. Kantola T, Kivist枚 KT, Neuvonen PJ (1998) Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 63:397–402
27. Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A (1998) Interaction between grapefruit juice and diazepam in humans. Eur J Drug Metab Pharmacokinet 21:55–59
28. Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR (1998) Grapefruit juice-felodipine interaction: effect of naringin and 6麓,7麓-dihydroxybergamottin in humans. Clin Pharmacol Ther 64:248–256
29. Hagelberg NM, Peltoniemi MA, Saari TI, Kurkinen KJ, Laine K, Neuvonen PJ, Olkkola KT (2010) Clarithromycin, a potent inhibitor of CYP3A, greatly increases exposure to oral S-ketamine. Eur J Pain 14:625–629
30. Peltoniemi MA, Saari TI, Hagelberg NM, Laine K, Neuvonen PJ, Olkkola KT (2011) St John’s wort greatly decreases the plasma concentrations of oral S-ketamine. Fundam Clin Pharmacol (in press). doi:10.1111/j.1472-8206.2011.00954.x
31. Peltoniemi MA, Saari TI, Hagelberg NM, Reponen P, Turpeinen M, Laine K, Neuvonen PJ, Olkkola KT (2011) Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine. Clin Pharmacol Ther 90:296–302
32. Noppers I, Olofsen E, Niesters M, Aarts L, Mooren R, Dahan A, Kharasch E, Sarton E (2011) Effect of rifampicin on S-ketamine and S-norketamine plasma concentrations in healthy volunteers after intravenous S-ketamine administration. Anesthesiology 114:1435–1445
33. Olkkola KT, Backman JT, Neuvonen PJ (1994) Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 55:481–485
34. Nivoix Y, Lev锚que D, Raoul H, Koffel J-C, Beretz L, Ubeaud-Sequier G (2008) The enzymatic basis of drug-drug interactions with systemic triazole antifungals. Clin Pharmacokinet 47:779–792
35. Michna E, Ross EL, Hynes WL, Nedeljkovic SS, Soumekh S, Janfaza D, Palombi D, Jamison RN (2004) Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse history. J Pain Symptom Manage 28:250–258
36. Feng N, Vollenweider FX, Minder EI, Rentsch K, Grampp T, Vonderschmitt DJ (1995) Development of a gas chromatography–mass spectrometry method for determination of ketamine in plasma and its application to human samples. Therap Drug Monit 17:95–100
37. Bond A, Lader M (1974) The use of analogue scales in rating subjective feelings. Br J Med Psychol 47:211–218
38. Hannington-Kiff JG (1970) Measurement of recovery from outpatient general anaesthesia with a simple ocular test. Br Med J 3:132–134
39. Stone BM (1984) Pencil and paper tests – sensitivity to psychotropic drugs. Br J Clin Pharmacol 18:15S–20S
40. Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, He K, Lown KS, Woster PM, Rahman A, Thummel KE, Fisher JM, Hollenberg PF, Watkins PB (1997) Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos 25:1228–1233
41. Guo LQ, Fukuda K, Ohta T, Yamazoe Y (2000) Role of furanocoumarin derivatives on grapefruit juice-mediated inhibition of human CYP3A activity. Drug Metab Dispos 28:766–771
42. Lin HL, Kent UM, Hollenberg PF (2005) The grapefruit juice effect is not limited to cytochrome P450 (P450) 3A4: evidence for bergamottin-dependent inactivation, heme destruction, and covalent binding to protein in P450s 2B6 and 3A5. J Pharmacol Exp Ther 313:154–164
43. Tassaneeyakul W, Guo LQ, Fukuda K, Ohta T, Yamazoe Y (2000) Inhibition selectivity of grapefruit juice components on human cytochromes P450. Arch Biochem Biophys 378:356–363
44. Bailey DG, Spence JD, Edgar B, Bayliff CD, Arnold JM (1989) Ethanol enhances the hemodynamic effects of felodipine. Clin Invest Med 12:357–362
45. Lilja JJ, Kivist枚 KT, Backman JT, Neuvonen PJ (2000) Effect of grapefruit juice dose on grapefruit juice–triazolam interaction: repeated consumption prolongs triazolam half-life. Eur J Clin Pharmacol 56:411–415
46. Lilja JJ, Backman JT, Laitila J, Luurila H, Neuvonen PJ (2003) Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol. Clin Pharmacol Ther 73:192–198
47. Tapaninen T, Neuvonen PJ, Niemi M (2010) Grapefruit juice greatly reduces the plasma concentrations of the OATP2B1 and CYP3A4 substrate aliskiren. Clin Pharmacol Ther 88:339–342
48. Nieminen TH, Hagelberg NM, Saari TI, Neuvonen M, Neuvonen PJ, Laine K, Olkkola KT (2010) Grapefruit juice enhances the exposure to oral oxycodone. Basic Clin Pharmacol Toxicol 107:782–788
49. Lilja JJ, Kivist枚 KT, Neuvonen PJ (1998) Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther 64:477–483
50. Lilja JJ, Kivisto KT, Backman JT, Lamberg TS, Neuvonen PJ (1998) Grapefruit juice substantially increases plasma concentrations of buspirone. Clin Pharmacol Ther 64:655–660
51. Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, Brown MB, Guo W, Watkins PB (1997) Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 99:2545–2553
52. Greenblatt DJ, von Moltke LL, Harmatz JS, Chen G, Weemhoff JL, Jen C, Kelley CJ, LeDuc BW, Zinny MA (2003) Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice. Clin Pharmacol Ther 74:121–129 - 作者单位：1. Department of Anesthesiology, Intensive Care, Emergency Care and Pain Medicine, University of Turku, P.O. Box 52, Kiinamyllynkatu 4-8, FI-20520 Turku, Finland2. Turku University Hospital, Turku, Finland3. Department of Anesthesiology, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany4. Department of Pharmacology, Drug Development and Therapeutics, University of Turku, Turku, Finland5. Unit of Clinical Pharmacology, Turku University Hospital, Turku, Finland6. Department of Clinical Pharmacology, University of Helsinki, Helsinki, Finland7. Helsinki University Central Hospital, Helsinki, Finland
- 刊物类别：Biomedical and Life Sciences
- 刊物主题：Biomedicine
Pharmacology and Toxicology - 出版者：Springer Berlin / Heidelberg
- ISSN：1432-1041
文摘
Purpose We examined the effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of oral S-ketamine.